Business
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2
About this update from Pharvaris N.v.
[{"type":"text","content":"ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST); the 2024 Eastern Allergy Conference (EAC); and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024. Details of the presentations are as follows: IDDST 2024. Osaka, Japan. May 22-24, 2024. Title: Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary AngioedemaPresenter: Anne Lesage, Ph.D.Format: Oral PresentationDate, time: Wednesday, May 22, 10:55-11:20 a.m. JST (Tuesday, May 21, 9:55-10:20 p.m. EDT) EAC 2024. Palm Beach, Florida, U.S. May 30-June 2, 2024. Title: Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema Presenter: Henry Li, M.D., Ph.D.Format: Poster PresentationDate, time: Saturday, June 1, 9:45-11:00 a.m. EDT EAACI Congress 2024. Valencia, Spain. May 31-June 3, 2024. Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 TrialPresenter: Emel Aygören-Pürsün, M.D.Format: Oral PresentationDate, time: Saturday, June 1, 17:21 CEST (11:21 a.m. EDT)Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary AngioedemaPresenter: Anna Valerieva, M.D., Ph.D.Format: Oral PresentationDate, time: Saturday, June 1, 17:33 CEST (11:33 a.m. EDT)Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial DesignPresenter: Marcus Maurer, M.D.Format: Poster (Flash Talk) PresentationDate, time: Sunday, June 2, 13:15 CEST (7:15 a.m. EDT)Title: Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema AttacksPresenter: Laurence Bouillet, M.D.,...